Urge your members of Congress to support continued medical research funding
ASH submitted comments to the National Cancer Institute (NCI) on ways in which improved childhood cancer data sharing could inform hematology-related pediatric research questions, data collection and data analysis tools.
ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.
Two big healthcare issues stand out as priorities for the 116th Congress; access to care and the cost of prescription drugs.
On December 14, 2018, a federal judge in Texas ruled that the Affordable Care Act (ACA) is unconstitutional now that Congress has eliminated the individual mandate penalty. There is no immediate impact on patients, providers or insurers, but if the decision, which may be appealed to the Supreme Court, is upheld, 20 million Americans could lose coverage and the protections for individuals with pre-existing conditions could be at risk.
ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.
ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.
In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.
In 2018, ASH commented on numerous rules and regulations proposed by the Centers for Medicare and Medicaid Services (CMS), which impact physician payment. ASH is actively involved in various advisory committees and also continues to engage with lawmakers on Capitol Hill.
During 2018, ASH continued to be highly visible in our advocacy for federal support of biomedical research and public health funding, including funding for the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC).
2018 was full of federal policies and proposals related to
access to care and drug pricing. The Administration made more changes to the
Affordable Care Act and highlighted that drug pricing is a priority.
Join the Grassroots Network to stay up to date on all of ASH’s Advocacy Campaigns.
Become an advocate for hematology with our easy-to-use advocacy resources.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology